NCT04641364View on ClinicalTrials.gov

Safety and Tolerance Study of Recombinant Human Albumin Injection in Healthy Subjects.

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 24, 2019

Primary Completion Date

May 6, 2020

Study Completion Date

May 6, 2020

Conditions
Ascites
Interventions
DRUG

recombinant human albumin injection

single dose or multiple doses of intravenous infusion

DRUG

Placebo

Single dose intravenous infusion of 0.9% sodium chloride injection

DRUG

human albumin injection

multiple doses of intravenous infusion

Trial Locations (1)

130021

the first hospital of Jilin University, Changchun

All Listed Sponsors
lead

The First Hospital of Jilin University

OTHER

NCT04641364 - Safety and Tolerance Study of Recombinant Human Albumin Injection in Healthy Subjects. | Biotech Hunter | Biotech Hunter